Del Giudice Matthew Paul
Transaction: 04/16/2026
BUY
Change
+50,000
Price
$1.34
Filing
07/27/2026
Type
BUY
Telomir Pharmaceuticals, Inc. Common Stock
TELO • Biotechnology
$1.01
▲ +0.00 (+0.18%)
Current price
EarningsLatest report: Jun 30, 2026
WEAK PROFILEWeakConfidence: 70%
Quantitative profile — not an investment recommendation.
Quantitative profile — not an investment recommendation.Methodology
Analysis thesis: Weak historical ratio profile. The current evidence does not support a favorable risk/reward view.
Market Cap
$61.36M
Growth
—
Cash Flow
0/5
Trend
Negative
Evidence
Manageable debt level · 0Healthy liquidity · 5.14Weak profitability
Financial data as of: Jun 30, 2026, 12:00 AM UTCLast earnings update: Jun 30, 2026, 12:00 AM UTCLast profile update: Aug 14, 2026, 12:31 PM UTC
Company Snapshot
Key valuation, quality, financial strength, momentum and analyst data.
Price$1.01
Change0.18%
Shares Out60.84M
Market Cap$61.36M
Enterprise Value$56.19M
52W Range0.89 - 2.09
Beta-0.24
P/E-1.18
P/B12.19
P/FCF-12.49
EV/EBITDA-13.37
EV/FCF-11.43
Price$1.01
Change0.18%
Shares Out60.84M
Market Cap$61.36M
Enterprise Value$56.19M
52W Range0.89 - 2.09
Beta-0.24
P/E-1.18
P/B12.19
P/FCF-12.49
EV/EBITDA-13.37
EV/FCF-11.43
Earnings Yield-84.73%
FCF Yield-8.01%
Dividend Yield0.00%
Gross Margin0.00%
Oper. Margin0.00%
Profit Margin0.00%
Debt/Eq0.00
Current Ratio5.14
Quick Ratio5.14
Target$4.00
Target Upside295.34%
Target Median$4.00
Target Range4.00 - 4.00
Volume86.52K
Avg Volume134.24K
EPS Surprise0.04
Investment DNA
How strong this company looks for long-term investors
38
out of 100
Business Quality
Margins, moat, returns
22/100
Financial Strength
Debt, cash, stability
70/100
Growth Potential
Revenue and expansion
50/100
Price Attractiveness
Cheap or expensive today
44/100
Why this score▼
Manageable debt level · 0Healthy liquidity · 5.14Weak profitability
Analyst view
Analyst sentiment and price target
Analyst sentiment
No vote count available
Bullish
0
Hold
0
Bearish
0
Price Target
2026-10-20
Low
$4.00
Mean
$4.00
Median
$4.00
High
$4.00
Insider Transactions
Recent executive and insider activity
⚠ 3 high-volume insider sells detected
MacPherson Edward Clouston
Transaction: 04/16/2026
BUY
Change
+50,000
Price
$1.34
Filing
07/27/2026
Type
BUY
Whalen Matthew Pratt
Transaction: 04/16/2026
BUY
Change
+50,000
Price
$1.34
Filing
07/27/2026
Type
BUY
| Insider | Type | Change | Price | Transaction | Filing |
|---|---|---|---|---|---|
| Del Giudice Matthew Paul | BUY | +50,000 | $1.34 | 04/16/2026 | 07/27/2026 |
| MacPherson Edward Clouston | BUY | +50,000 | $1.34 | 04/16/2026 | 07/27/2026 |
| Whalen Matthew Pratt | BUY | +50,000 | $1.34 | 04/16/2026 | 07/27/2026 |
| Mushak Andriy | OTHER | 0 | Not reported | 06/03/2026 | 06/09/2026 |
| Del Giudice Matthew Paul | SELL | -25,000 | $5.02 | 05/21/2026 | 05/22/2026 |
| MacPherson Edward Clouston | SELL | -25,000 | $5.02 | 05/21/2026 | 05/22/2026 |
| Whalen Matthew Pratt | SELL | -25,000 | $5.02 | 05/21/2026 | 05/22/2026 |
| Aminov Erez | SELL | -1,960,170 | $5.02 | 05/21/2026 | 05/22/2026 |
| Aminov Erez | SELL | -2,000,000 | $2.10 | 05/21/2026 | 05/22/2026 |
| Aminov Erez | BUY | +7,319,710 | $1.37 | 04/22/2026 | 04/24/2026 |
| MIRA PHARMACEUTICALS, INC. | OTHER | 0 | Not reported | 09/29/2025 | 10/03/2025 |
| Weichselbaum Alan | OTHER | +50,000 | $2.75 | 05/15/2025 | 06/10/2025 |
| Aminov Erez | BUY | +400,000 | Not reported | 05/28/2025 | 05/30/2025 |
| Aminov Erez | BUY | +2,000,000 | $2.10 | 05/28/2025 | 05/30/2025 |
| Aminov Erez | OTHER | 0 | Not reported | 12/31/2024 | 02/04/2025 |
| Bay Shore Trust | SELL | -100,000 | $3.73 | 11/21/2024 | 11/25/2024 |
| Yanez Michelle | BUY | +200,000 | $5.02 | 08/27/2024 | 09/04/2024 |
| Whalen Matthew Pratt | BUY | +25,000 | $5.02 | 08/27/2024 | 08/29/2024 |
| Del Giudice Matthew Paul | BUY | +25,000 | $5.02 | 08/27/2024 | 08/29/2024 |
| Aminov Erez | BUY | +1,960,170 | $5.02 | 08/27/2024 | 08/29/2024 |